The hypothalamic neuropeptide oxytocin not only modulates psychosocial function, but also contributes to metabolic regulation. We have recently shown that intranasal oxytocin acutely improves beta-cell responsivity and glucose tolerance in normal-weight men. In the present experiment, we investigated the acute glucoregulatory impact of oxytocin in obese men with impaired insulin sensitivity. 
The hypothalamic neuropeptide oxytocin not only modulates psychosocial function, but also contributes to metabolic regulation. We have recently shown that intranasal oxytocin acutely improves beta-cell responsivity and glucose tolerance in normal-weight men. In the present experiment, we investigated the acute glucoregulatory impact of oxytocin in obese men with impaired insulin sensitivity. Fifteen obese healthy men with an average body mass index of 35 kg/m 2 and an average body fat content of 33% received a single intranasal dose (24 IU) of oxytocin before undergoing an oral glucose tolerance test. Results were analysed according to the oral minimal model and compared with our findings in normal-weight participants. In contrast to the results in normal-weight subjects, oxytocin did not blunt postprandial glucose and insulin excursions in obese men, and moreover failed to enhance beta-cell responsivity and glucose tolerance. These results indicate that pronounced obesity may be associated with a certain degree of resistance to the glucoregulatory impact of exogenous oxytocin, and underlines the need for further investigations into the potential of oxytocin to improve glucose homeostasis in the clinical context.
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| INTRODUCTION
The hypothalamic neuropeptide oxytocin has been shown to suppress food intake, increase energy expenditure and enhance glucose homeostasis. 1 Thus, early human studies showed that intravenous oxytocin increases insulin secretion. 2 Intranasal oxytocin administration was found to reduce fasting insulin concentrations 3 and blunt glucose responses to food intake. 4, 5 In healthy normal-weight men, intranasal oxytocin acutely improved β-cell responsivity and more than doubled the disposition index (DI) that reflects glucose tolerance. 6 However, the impact of oxytocin on glucose homeostasis in obese humans with associated impairments in insulin sensitivity has not been systematically investigated. In pilot experiments in obese and overweight participants, 8 weeks of intranasal oxytocin administration induced weight loss, but did not modulate fasting glucose and insulin levels, 7 leaving open the question whether with an increase in body weight, oxytocin might lose some of its glucoregulatory impact. Overweight-and obesity-associated decreases in the sensitivity to glucoregulatory hormones are well known, most prominently in the case of peripheral, but also central insulin action. 8 In the present experiment in obese men, we tested the effect of intranasal oxytocin on glucose homeostasis as assessed by an oral glucose tolerance test (OGTT) followed by oral minimal model analysis, 9 and compared our findings with the results in normal-weight men, which were obtained with an identical experimental set-up. 6 2 | METHODS
| Subjects
Power calculations (G*Power Version 3.0.10, Heinrich-Heine University Düsseldorf, Germany) based on our previous study in normalweight men, 6 
| Experimental procedure
Experiments were performed in a double-blind, cross-over, withinsubject, balanced comparison. Each subject participated in two sessions (oxytocin/placebo) with a minimum of 14 days in between. Subjects were instructed to remain fasted with the exception of drinking water after 2000 hours on the day preceding each session.
Participants arrived at the lab at 0800 hours and a venous cannula was inserted. Blood was repeatedly sampled (with baseline measurements at 0840 and 0855 hours) and blood pressure and heart rate were measured throughout the experiment. At 0910 hours, 12 0.1-mL puffs (6 per nostril) of oxytocin (Syntocinon, Defiante Farmacêutica, Funchal, Madeira, Portugal) or placebo (vehicle containing the same ingredients except the hormone) were intranasally administered by a nebulizer at 30-second intervals, amounting to 24 IU oxytocin. This dose was likewise administered in our previous study in normal-weight men 6 and is also known to reduce calorie intake in obese men. 
| Oral minimal model
The method 9 3 | RESULTS
| Subject characteristics
Fifteen healthy obese men participated in the study (age AE SEM, Table S1 for subject characteristics).
| Oxytocin and glucose homeostasis
In the obese subjects, baseline concentrations of blood parameters were comparable between conditions (P > 0.08). Plasma oxytocin concentrations were increased about 6-fold 20 minutes after administration and remained significantly elevated thereafter (F 2,34 = 9.76; P < 0.001 for Treatment × Time; Figure 1A ). Glucose concentrations did not differ between conditions (P > 0.7; P > 0.9 for the first h of the OGTT; Figure 1B ). Insulin and C-peptide concentrations were generally comparable between conditions (P > 0.2), with single time-point comparisons indicating increases 30 minutes after the glucose load (P = 0.014 and P = 0.058, respectively; Figure 1C ,D).
In comparison with our previous results in normal-weight men, 6 baseline insulin and C-peptide concentrations along with HOMA-IR values were higher in the obese men (Table S2, 
Circulating oxytocin concentrations and parameters of glucose homeostasis. Mean AE SEM plasma or serum concentrations of (A) oxytocin, (B) glucose, (C) insulin and (D) C-peptide at baseline and after administration of 24 IU oxytocin (black circles) or placebo (white circles). Oxytocin or placebo was administered at 0910 hours followed by the OGTT (75 g glucose) 1 hour later, at 1010 hours. The bottom panels depict oral minimal model-derived estimates of (E) glucose disposal (DI) and (F) β-cell responsivity (Φ tot ) in the oxytocin (black bars) and placebo (white bars) conditions. t P ≤ 0.1, *P ≤ 0.05, **P < 0.01, ***P < 0.001, as derived from paired t-tests; n = 15 AUC 1010-1110h values of insulin and C-peptide (Table S3 , Supporting Information).
| Oral minimal model
In the obese participants, oxytocin did not affect model-derived parameters of glucose metabolism (all P > 0.1), including glucose tolerance as reflected by DI (P > 0.3; Figure 1E ), insulin sensitivity (P > 0.1) and Φ tot ( Figure 1F ) and its components, Φ b , Φ s and Φ d (all P > 0.2).
Comparisons between groups indicated body weight-related differences in the oxytocin effect for S I (P = 0.029), DI (P = 0.061), and Φ tot (P < 0.001), reflecting the improving effect of oxytocin on glucose disposal, beta-cell responsivity and insulin sensitivity seen in the normalweight, but not the obese men.
3.4 | Counter-regulatory hormones, NEFA, energy expenditure and control parameters
In the obese subjects, oxytocin did not affect ACTH and cortisol (all P > 0.05; Figure 2A ,B) or glucagon (P > 0.1; Figure 2C ) and NEFA concentrations (P > 0.5). Oxytocin neither modulated energy expenditure and haemodynamic measures (all P > 0.5) nor any of the psychological parameters (P > 0.09). These results are largely comparable with the findings in the normal-weight subjects. 6 
| DISCUSSION
We show that in contrast to our previous finding of oxytocin-induced improvements in glucose tolerance and β-cell responsivity in normalweight men, 6 oxytocin does not acutely improve glucose homeostasis in obese men. These results are in line with the lack of effects on fasting glucose and insulin concentrations in obese and overweight participants who received intranasal oxytocin at a dose of 96 IU/d for 8 weeks. 7 In some contrast to the present results, intranasal oxytocin suppressed postprandial glucose levels after breakfast intake in normal-weight and obese men alike. 5 Notably, the obese men of the present study had a mean BMI of 35.3 kg/m 2 and markedly elevated body fat of around 40 kg, values that clearly exceeded those of the obese subjects in the previous study 5 (32.1 kg/m 2 and 26.5 kg). This pattern suggests that oxytocin loses its glucoregulatory efficacy with increasing adiposity, a conclusion that is supported by our observation that across the body weight spectrum of the present and our previous experiments on glucoregulation, 6 the glucose-lowering effect of oxytocin decreased with rising BMI, fat mass and HOMA-IR. The obese subjects of the present study also had a more pronounced insulin resistance than overweight subjects who displayed oxytocin-induced decreases in insulin concentrations in a study by Lawson and colleagues 3 (HOMA-IR, 3.7 AE 1.7 vs. 2.1 AE 0.4).
The notion that elevated body fat impairs the glucoregulatory efficacy of oxytocin relates to the question of endogenous oxytocin release in metabolic disorders. While lower oxytocin concentrations were found in obese compared with normal-weight adults 10 and children, 11 oxytocin levels have also been found to be proportional to
FIGURE 2 Counterregulatory hormones. Mean AE SEM plasma or serum concentrations of (A) ACTH, (B) cortisol and (C) glucagon at baseline and after administration of 24 IU oxytocin (black circles) or placebo (white circles). Oxytocin or placebo was administered at 0910 hours followed by the OGTT (75 g glucose) 1 hour later at 1010 hours. t P ≤ 0.1, *P ≤ 0.05, as derived from paired t-tests; n = 15 body weight. 12, 13 In a large sample of men with metabolic syndrome, oxytocin concentrations were elevated compared with healthy controls, 14 whereas the obese subjects of the present experiment displayed lower baseline oxytocin levels than their lean counterparts.
Decreased oxytocin concentrations were reported in patients with metabolic syndrome or diabetes mellitus, 10, 11, 15, 16 suggesting a certain degree of oxytocin deficiency in diabetic patients. 1 However, our pre- The contribution of central and peripheral pathways to the metabolic effects of intranasally administered oxytocin is a matter of ongoing investigation. [17] [18] [19] [20] Assuming that its impact on glucose regulation involves central 21 as well as peripheral mediators, 22 it remains to be seen how the possible resistance to oxytocin's glucoregulatory effect in obesity that is suggested by the present results can be overcome.
Signs of enhanced insulin release upon oxytocin administration that might mediate some of its beneficial impact on glucose homeostasis 6 were also found in the obese subjects of the present experiment.
Future studies, which should include larger sample sizes and female subjects as well as, in particular, diabetic patients, may therefore investigate the effect of different dose regimens and of interventions that specifically target central or peripheral sites of action.
